Everyone at some point in their life may need to take medication to treat an illness or disease. By finding new and better ways to create drugs, the COST Action Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig) helped improve the effectiveness and safety of the medications, which can ultimately benefit people's health and well-being.
Inspired by the Paul Ehrlich Euro-PhD network, and launched successfully in 2015, MuTaLig has focused on innovative drug discovery. Researchers embraced the 'multi-target paradigm', developing drugs that can interact with multiple protein targets using a single compound. This strategy enhances drug effectiveness, minimizes resistance, and reduces side effects. Consequently, these compounds can better combat complex diseases like cancer, Alzheimer's, and diabetes, leading to improved health outcomes and quality of life for patients
We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.
Professor Stefano Alcaro from Università Magna Graecia di Catanzaro (UMG) and the Chair of the Action MuTaLig shares with us the insights of this 'multi-target paradigm' which became particularly relevant during the pandemic. "Because the 'drug repurposing' or 'drug repositioning' is a method for revaluating old drugs or natural agents for other cures", says Stefano.
